Drug intelligence / Profile preview

CTX-030916

Development stage: Preclinical
Lead developer: Context Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

CTX-030916 is an investigational, orally bioavailable small molecule progesterone receptor (PR) antagonist being developed by Context Therapeutics. It is primarily targeted for the treatment of women's health conditions, specifically uterine leiomyoma (uterine fibroids). By antagonizing the progesterone receptor, CTX-030916 aims to inhibit the growth and maintenance of fibroid tissue, which is heavily influenced by progesterone signaling. This targeted hormonal approach is intended to provide a non-invasive therapeutic alternative to surgical interventions for managing fibroid-related symptoms.

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on CTX-030916.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTX-030916.

Explore the full profile